معرفی
Chang-Guo Zhan is a University Research Professor and Professor of Pharmaceutical Sciences at the UK College of Pharmacy, leading the Molecular Modeling and Biopharmaceutical Center (MMBC) and Chemoinformatics & Drug Design Core. Holding dual PhDs in Chemistry (Notre Dame) and Molecular Physics (Japan's Institute for Molecular Science), he specializes in computational-experimental drug discovery. His lab develops novel therapeutics targeting addiction, inflammation, and cancer through integrated approaches, with two agents in Phase II trials. Notable achievements include FDA Breakthrough Therapy status for a cocaine hydrolase and a 2025 NIH-funded sepsis therapy. He has published 350+ papers, 37 patents, and received major awards including the AAPS Research Achievement Award (2016) and ACS Emerging Technology Prize (2005).
Research focuses on structure-based drug design, protein engineering, and translational medicine. Key projects include cocaine hydrolase development, mPGES-1 inhibitors for aortic aneurysms, and computational tools for pandemic response. Collaborations span experimental labs globally, with funding from NIH, NSF, and DoD. Training over 50 graduate/postdoctoral researchers, his lab emphasizes interdisciplinary approaches combining AI, molecular modeling, and wet lab validation.
- Education: PhDs in Chemistry (1996) & Molecular Physics (1997), Postdoc at Columbia University (1997-2000)
- Awards: AAPS Fellow (2010), 2025 Breakthrough Therapy Designation (FDA)
- Leadership: Editorial Board member of multiple journals, Chair of AAPS Computational Drug Design Focus Group
Current studies explore polydrug interactions, opioid abuse therapies, and AI-driven drug discovery. His lab's unique 'computational-experimental' paradigm accelerates translation from bench to clinic, with particular emphasis on enzyme stabilization and protein pharmaceuticals.
